

## Rogaratinib

## Chemical Properties

CAS No. : 1443530-05-9


Formula: C<sub>23</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub>S

Molecular Weight: 466.56

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity.
Targets(IC50)	FGFR
In vitro	A novel pan-FGFR inhibitor, rogaratinib, in biochemical, cellular and in vivo efficacy studies in a variety of preclinical cancer models. In vitro kinase activity assays demonstrate that rogaratinib potently and selectively inhibits the activity of FGFRs 1, 2, 3 and 4. In line with this, rogaratinib reduced proliferation in FGFR-addicted cancer cell lines of various cancer types including lung, breast, colon and bladder cancer. FGFR and ERK phosphorylation interruption by rogaratinib treatment in several FGFR-amplified cell lines suggests that the anti-proliferative effects are mediated by FGFR/ERK pathway inhibition[1].

## Solubility Information

Solubility	DMSO: 5.5 mg/mL (11.79 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.1433 mL	10.7167 mL	21.4335 mL
5 mM	0.4287 mL	2.1433 mL	4.2867 mL
10 mM	0.2143 mL	1.0717 mL	2.1433 mL
50 mM	0.0429 mL	0.2143 mL	0.4287 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Sylvia Grünewald , Oliver Politz , Sebastian Bender, et al. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. *Int J Cancer*. 2019 Sep 1;145(5): 1346-1357.

Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. *Oncogenesis*. 2016 Jul 18;5(7):e241.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481